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sclerosis - a systematic review
Robert Simpson1*, Jo Booth2, Maggie Lawrence2, Sharon Byrne1, Frances Mair1 and Stewart Mercer1Abstract
Background: Multiple sclerosis (MS) is a stressful condition; depression, anxiety, pain and fatigue are all common
problems. Mindfulness based interventions (MBIs) mitigate stress and prevent relapse in depression and are
increasingly being used in healthcare. However, there are currently no systematic reviews of MBIs in people with
MS. This review aims to evaluate the effectiveness of MBIs in people with MS.
Methods: Systematic searches were carried out in seven major databases, using both subject headings and key
words. Papers were screened, data extracted, quality appraised, and analysed by two reviewers independently,
using predefined criteria. Study quality was assessed using the Cochrane Collaboration risk of bias tool. Perceived
stress was the primary outcome. Secondary outcomes include mental health, physical health, quality of life, and
health service utilisation. Statistical meta-analysis was not possible. Disagreements were adjudicated by a third party
reviewer.
Results: Three studies (n = 183 participants) were included in the final analysis. The studies were undertaken in
Wales (n = 16, randomised controlled trial - (RCT)), Switzerland (n = 150, RCT), and the United States (n = 17,
controlled trial). 146 (80%) participants were female; mean age (SD) was 48.6 (9.4) years. Relapsing remitting MS was
the main diagnostic category (n = 123, 67%); 43 (26%) had secondary progressive disease; and the remainder were
unspecified. MBIs lasted 6–8 weeks; attrition rates were variable (5-43%); all employed pre- post- measures; two had
longer follow up; one at 3, and one at 6 months. Socio-economic status of participants was not made explicit;
health service utilisation and costs were not reported. No study reported on perceived stress. All studies reported
quality of life (QOL), mental health (anxiety and depression), physical (fatigue, standing balance, pain), and
psychosocial measures. Statistically significant beneficial effects relating to QOL, mental health, and selected physical
health measures were sustained at 3- and 6- month follow up.
Conclusion: From the limited data available, MBIs may benefit some MS patients in terms of QOL, mental health,
and some physical health measures. Further studies are needed to clarify how MBIs might best serve the MS
population.
Keywords: Multiple sclerosis, Mindfulness, Stress managementBackground
Multiple sclerosis (MS) is a chronic, unpredictable, and
poorly understood neurodegenerative inflammatory condi-
tion [1]. Nervous system damage can be extensive, with se-
vere disability in both physical and cognitive realms [2,3].
Worldwide incidence of MS is increasing, with estimates at
3.6/100,000 person-years in females and 2.0/100,000
person-years in men [4]. MS can present in myriad* Correspondence: Robert.Simpson@glasgow.ac.uk
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stated.different ways and carries a high degree of uncertainty, in
terms of disease progression and resultant impairment
[5-7]. MS characteristically falls into several different diag-
nostic subclassifications, depending on disease activity and
stage of progression [8,9].
MS typically follows a chronic and eventually progressive
course. Consequently, health service utilisation costs accu-
mulate and impact significantly on resource allocation [10].
Epidemiological data from the United States, Canada, and
China all highlight comorbidity as problematic [11-14],
with mental health diagnoses frequently co-existing. Theal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
ain/zero/1.0/) applies to the data made available in this article, unless otherwise
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lence estimates of up to 16.5% and 46%, respectively [15].
Health related quality of life (HRQOL) is often significantly
impaired in people with MS [16], and may be exacerbated
by disease uncertainty [5] and depression [13]. Mental
health comorbidity is thought to be under-reported in
people with MS [15,17] and is associated with diminished
treatment adherence, increased somatic symptoms, and im-
pairment of both functional ability, and social status [18].
As in many chronic illnesses, self-efficacy is of importance
in people with MS. Enhanced feelings of control and ac-
ceptance may lessen the psychological and emotional im-
pact of living with a chronic condition, and contribute to
improvements in clinical status, such as diminished fatigue
[19,20].
Psychological distress may contribute to MS disease ac-
tivity [21], and a growing body of research evidence exam-
ines this hypothesis [22,23]. Cognitive behavioural therapy
(CBT) has already been found to impact positively upon
psychological stress [24] and pathological neuroimaging
markers; the short term effect size for such CBT interven-
tions has been shown in one study to rival that of certain
disease modifying pharmacological agents [22].
Mindfulness based interventions
Mindfulness practices originate from ancient Buddhist
meditation techniques, but have since been secularised,
manualised, and appropriated for use in a diverse range of
clinical settings. Jon Kabat-Zinn, who introduced Mindful-
ness techniques to the West in the nineteen eighties, has
defined Mindfulness as: ‘..paying attention in a particular
way: on purpose, in the present moment, and nonjudge-
mentally’ [25]. The original research studies on Mindfulness
focussed on chronic pain, but Mindfulness-based interven-
tions (MBIs) have become increasingly popular in various
areas of chronic disease management over the last 30 years.
Group-oriented, Mindfulness Based Stress Reduction
(MBSR) is the most well researched MBI approach and has
been applied in the management of: anxiety, chronic pain,
depression, and stroke [26-29]. MBSR appears to have neu-
roendocrine, immunological and neuroplastic effects, al-
though research in this area remains explorative in nature
[30-33]. MBSR classically consists of instruction in three
meditation techniques, namely breath awareness, body
awareness, and dynamic yoga postures (mindful move-
ment) [34] taught in groups over 8 weeks. Mindfulness
Based Cognitive Therapy (MBCT) is a derivative of MBSR,
with a greater emphasis on cognitive techniques, designed
for specific mental health conditions such as recurrent de-
pression [35].
Why is it important to undertake a review of MBIs?
The mitigation of stress is proposed as a means to ac-
tively manage and reduce pathological disease activity inpeople with MS [22]. Indeed, a CBT intervention has
already demonstrated efficacy, reducing gadolinium le-
sion enhancement on neuroimaging during the active
period of treatment. However, this effect is not sustained
on cessation of therapist input [22]. MBIs are thought to
operate in a different manner to CBT [36] and might
have a more sustained effect, given the strong emphasis
on regular self-practice. To date and as far as we are
aware, no systematic review of the evidence for MBIs in
people with MS has been published. This paper aims to
evaluate the effectiveness of MBIs in people with MS.
Methods
Search strategy
In May 2013 a systematic search for published and un-
published studies was conducted in six major electronic
bibliographic databases: Cochrane Central Register of
Controlled Trials, MEDLINE, EMBASE, CINAHL, Al-
lied and Complementary Medicine Database, and Psy-
cInfo. To identify any additional published and/or
unpublished trials, we also searched ProQuest Disserta-
tions & Theses Database and contacted MS/mindfulness
researchers. Selected medical subject headings were
combined with key words relating to MS and mindful-
ness to create a search strategy which was finalised for
use in MEDLINE (see Additional file 1) and amended
for use in the other databases, using appropriate con-
trolled vocabulary, Boolean operators, and search sym-
bols. Delimiters were: dates searched (1980–2013);
research subjects (human); and language (English). The
search included the grey literature, using reference lists
and citation searching from reviews and published trials,
the Science Citation Index, and also involved consulting
noted experts in the field. Endnote was used to store
and manage the results of the database searches.
Selection criteria
Studies were selected for inclusion using criteria related to
the Study design, Participants, Interventions, and Out-
comes model (SPIO). SPIO is an adapted version of PICOs
(Population, Interventions, Comparison, and Outcomes)
[37]. Any definite diagnosis of MS in an adult (>18 years)
was acceptable for inclusion in the review. MBIs can vary
by both name and range of ingredients; therefore a core
content of: breath awareness, body awareness, and mindful
movement, comparable to that of the standardized MBSR,
was decided upon as a pre-requisite for inclusion. MBSR
was chosen as it represents the original model introduced
by Jon Kabat-Zinn in the nineteen eighties, which has been
widely described and researched since its inception.
Perceived stress was the primary outcome measure sought.
Secondary outcome measures included: mental health,
physical health, psychosocial measures, as well as health
care utilisation.
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The bibliographic records identified by the searches
were screened for relevance using broad inclusion cri-
teria, i.e. ‘multiple sclerosis’ and ‘mindfulness’ . All rele-
vant papers were then screened, using the SPIO
inclusion criteria (Table 1), to select eligible papers. All
selected papers were subject to methodological appraisal.
As the search yielded low numbers, a decision was made
not to exclude studies solely on the basis of poor meth-
odological quality. Screening methods were based on the
Systematic Reviews guidance outlined in the Centre for
Reviews and Dissemination (CRD) [38]. Methodological
issues are discussed below and reported in the evidence
table (Table 2).Quality appraisal
Risk of bias was assessed using the Cochrane Collabora-
tion’s assessment tool [39] to summarise the risk of bias for
major outcomes. The evidence for each individual outcome
was graded as low, unclear, or high risk. This included
assessing for evidence of: sequence generation; allocation
concealment; blinding of participants, personnel and out-
come assessors; incomplete outcome data; selective out-
come reporting; and any other sources of bias.Data extraction
The authors developed a data extraction tool, adapted from
a previous systematic review examining the benefits of
MBIs following transient ischaemic attack and stroke [29].
The data extracted included information on study design
and methodology, the populations under review, the inter-
ventions being employed, and the outcomes recorded in
each study. Two reviewers working independently carried
out screening and data extraction. Broad screening was
undertaken by RS and SB; narrow screening by RS and JB.
Any disagreements were adjudicated via a further reviewer
(SM).Table 1 SPIO narrow screen inclusion/exclusion criteria
Inclusion criteria Exclusion criteria
Study design Randomised controlled
trial, controlled trial
Qualitative studies
Single case study
Systematic reviews
Literature reviews
Guidelines Audit
Population Age >18 years Any
diagnosis of MS
<18 years old Diseases
other than (and not
including) MS
Intervention Any specifically
mindfulness-based
intervention (MBI)
Psychotherapy Drug
treatments Manual
therapy (ie massage)
Outcomes Perceived stress Anxiety
Depression HRQOL Pain
Personal wellbeing Social
participationData synthesis
As the results of the search and review were heterogenous,
findings are presented in a narrative format. It was not pos-
sible to undertake a meta-analysis.
Results
The search of the databases retrieved 1,049 records. Fol-
lowing screening (Figure 1), 3 papers were considered
eligible for inclusion in the review: Grossman et al. [40],
Mills and Allen [41], and Tavee et al. [42]. See
Additional file 2 for details of papers excluded by narrow
screening. Further information on study findings was
sought from authors Mills and Allen [41] and Tavee
et al. [42], but no responses were received.
Study characteristics
The three studies originated from Wales (Mills and
Allen [41]), Switzerland (Grossman et al. [40]), and the
United States (Tavee et al. [42]). Grossman et al. [40]
and Mills and Allen [41] conducted randomised con-
trolled trials (RCT), while Tavee et al. [42] reported a
non-randomised controlled trial. None of the studies
compared MBIs against an active intervention. Grossman
et al. [40] recruited from Neurology out-patients, and
conducted the study in a university hospital setting,
as did Tavee et al. [42]. Mills and Allen [41] recruited
from a mixture of General Practitioner and Physiothe-
rapist referrals.
Across the studies, there was a total of 183 partici-
pants. Attrition was variable. Grossman et al. [40] de-
scribed remarkably low attrition rates (5%) and a high
attendance rate (92%), whilst Mills and Allen [41] re-
ported drop out rates of 12.5% and cited reasons such as
bereavement and dislike of Tai Chi style exercises. Tavee
et al. [42] had the highest attrition of all (43%), and cited
issues such as transportation and a lack of interest.
Tavee et al. [42] presented results for a mixed study
population i.e. people with MS and patients with Peri-
pheral Neuropathy. As we were unable to obtain MS-
only data, this limited interpretation of their findings.
Grossman et al. [40] collected data at 3 points (pre- and
post- intervention, and at 6-month follow up), while
Mills and Allen [41] recorded data at pre-, post- and 3
months after the intervention. Tavee et al. [42] only re-
corded data at pre- and immediately post-intervention.
See Table 2 for details.
Intervention characteristics
Grossman et al. [40] delivered an intervention closely
mapped to MBSR. Mills and Allen [41] and Tavee et al.
[42] used less standardised versions, introducing elements
of Tai Chi and Qi Gong. However, all three studies were
broadly comparable in content, with all three emphasising
mindful breath awareness, mindful movement, and body
Table 2 Study characteristics
Study (country) Study design
(setting)
Sample size
(attrition %)
Type of intervention
(duration)
Outcome measures Data
collection
Mills and Allen
[41] (Wales)
RCT (Patients
home)
n = 16
(12.5%)
Mindful breathing Mindful movement (Tai Chi) Self
compassion Home study material (6/52 duration)
POMS Standing balance
Symptom rating
questionnaire
Baseline
Post
intervention
3 months post
intervention
Grossman et al.
[40] (Switzerland)
RCT
(University
hospital)
n = 150 (5%) Mindful breathing Mindful movement (Yoga) Body
scan Home study material (8/52 duration)
CES-DSTAI MFIS HAQUAMS
PQOLC Neuropsych.
Baseline
Post
intervention
6 months post
intervention
Tavee et al. [42]
(United States)
CT (University
hospital)
n = 17 (43%) Mindful breathing (Samatha) Mindful movement
(Tai Chi) Walking meditation (8/52 duration)
SF-36 MFIS VAS Physical
role Vitality PDDS
Baseline
Post
intervention
NR
1. RCT - Randomised controlled trial; 2. CT - Controlled trial; 3. CES-D Center for epidemiological studies depression scale ; 4. HAQUAMS - Hamburg quality of life
questionnaire in multiple sclerosis (German); 5. MFIS - Modified fatigue impact scale; 6. POMS - Profile of mood states; 7. PQOLC - Profile of health related quality
of life in chronic disorders (German); 8. SF-36 - Short form 36; 9. STAI - Spielberger trait anxiety inventory; 10. VAS - Visual analogue scale for bodily pain;
11. PDDS - Patient Determined Disease Steps; 12. Neuropsych. - Neuropsychological assessment; 13. NR - not recorded.
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of the studies, but the Mills and Allen [41] intervention was
delivered one to one.
Grossman et al. [40] used certified and experienced
MBI teachers to deliver the MBI over 8 weekly 2.5 hour
sessions, with a 7 hour session at week 6. They empha-
sised mindfulness practices in the sitting, lying and yoga
asana postures, and also encouraged ‘homework’ prac-
tices for 40 minutes daily. They were the only investiga-
tors to record homework practice times. Tavee et al. [42]
delivered a 4 hour introductory group session, followed
by 8 weekly 1.5 hour classes, with a Buddhist Monk
teaching all of the course components, including
Samatha meditation (sitting and observing the breath),
and mindful movement in the form of Tai Chi/Qi Gong
and walking meditation. Tavee et al. [42] encouraged
home practice, but did not record frequencies. Mills and
Allen [41] delivered six individualised sessions in which
unspecified teachers taught mindful movement with Tai
Chi/Qi Gong, with breath and posture awareness, whilst
encouraging participants to cultivate compassionate feel-
ings towards themselves. Mills and Allen [41] also pro-
vided self study material, but did not report on
participant uptake and usage by participants. Please see
Table 2.
Participant characteristics
None of the studies provided data regarding ethnicity of
participants. Across the three studies, 80% (n = 146) of
participants were female, and the mean (SD) age of the
total sample (n = 183) was 48.6 (9.4) years. Data regard-
ing socioeconomic status was generally not well re-
ported; for example, Mills and Allen [41] provided dataon only half of their study population, of whom, 50%
were in employment. Grossman et al. [40] recorded
number of years in education. Disease phenotype was
described in two of the studies; however, Tavee et al. [42]
simply described participants (n = 17) as having any
diagnosis of MS. From the remaining 166 patients where
a phenotype could be discerned, 123 (67%) had a diag-
nosis of relapsing remitting MS, and the other 43 (25%)
were diagnosed with secondary progressive MS. All
three studies excluded patients with significant cognitive
impairment, as well as those with severe physical disabil-
ity, according to either the Expanded Disability Status
Scale being >6 (requiring 2 walking aids i.e. a pair of
canes, crutches, etc. - in order to walk about 20 meters,
without resting), or more generally, being unable to
make their own way to the hospital (Mills and Allen
[41]). See Table 3.
Outcomes
The primary outcome sought by this review (perceived
stress) was not reported in any of the studies. However,
secondary outcomes of interest included: anxiety, de-
pression, HRQOL, concentration, fatigue, vitality and
general wellbeing. No information was available on eco-
nomic parameters, such as cost/benefit analysis for pa-
tients, or health service utilisation. Please see Table 2.
Mental health outcomes
Anxiety
Grossman et al. [40] measured anxiety directly with the
Spielberger Trait Anxiety Index (STAI), demonstrating
significant reduction immediately post completion in
Figure 1 Search results flow diagram.
Table 3 Participant characteristics
Mills and Allen [41] Grossman et al. [40] Tavee et al. [42]
Ethnicity NR NR NR
Number of participants (% female) 16 (80%) 150 (80%) 17 (78%)
Mean age (SD) 49.8 (6.8) 47.3 (10.3) 48.7 (11.2)
Socio-economic status NR NR NR
Employment status 4 employed (25%) NR NR
Mean years of education (SD) NR 14.1 (1.9) NR
Disease phenotype SP 16 (100%) RR 123 (82%) SP 27 (18%) NR
Stage in disease progression NR Mean EDSS 3.0 (1.1) Mean EDSS 3.0 (2.5)
Comorbidities NR NR NR
Number of patients on disease modifying medication NR 91 (60.1%) NR
Number of patients on psychotropic medication NR 30 (20%) NR
1. SP - Secondary Progressive; 2. RR - Relapsing Remitting; 3. EDSS - Expanded disability status scale; 4. NR - Not recorded.
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analyses of those with evidence of pre-intervention im-
pairment. This was maintained at six-month follow up
in overall group and subgroup analyses. Mills and Allen
[41] included data on change in anxiety scores via a gen-
eral MS symptom checklist, and the Profile of Mood
States (POMS), reporting non-significant change. Please
refer to Table 4.
Depression
Two studies assessed the effect of MBIs on depression.
Grossman et al. [40] used the Center for Epidemiological
Studies Depression (CES-D) scale, reporting significant
reductions in both whole intervention group and sub-
group analyses of those with pre-intervention impair-
ment at intervention completion. This was maintained
at six-month follow up in the overall group and in sub-
group analyses. Mills and Allen [41] also reported a sig-
nificant change using the POMS scale. See Table 4.
Physical outcomes
Standing balance
Mills and Allen [41] reported preferentially on physical
measures, opting to focus on single-leg standing balance,
with significant improvement noted at both study com-
pletion and at three-month follow up, although one par-
ticipant’s data was missing for this latter calculation.
Please see Table 5.
Pain
At study completion, Tavee et al. [42] described a signifi-
cant reduction in bodily pain, as measured by the Visual
Analogue Scale (VAS). See Table 5.
Fatigue
All three studies measured the effect of MBIs on fatigue.
Scores on the Modified Fatigue Impact Scale (MFIS)
were significantly reduced in the study by Grossman
et al. [40] at both intervention completion in the overall
population, as well as in subgroup analyses of those with
pre-intervention impairment. Beneficial effect wasTable 4 Mental health outcomes
Study Outcome (measure) Post
Grossman et al. [40] Full intervention group Anxiety (STAI)
Sub-group analysis
Full intervention group Depression (CES-D)
Sub-group analysis
Mills and Allen [41] Anxiety (POMS)
Depression (POMS)
1. STAI - Spielberger Trait Anxiety Index; 2. CES-D - Centre for Epidemiological Studi
*Effect size not recorded.maintained in the overall group at six-months, as well as
in those with pre-intervention impairment. Tavee et al.
[42] also reported significant change on MFIS at study
completion. Fatigue was non-significantly reduced on
POMS in the Mills and Allen [41] study see Table 5.
Psychosocial outcomes
Grossman et al. [40] measured both disease-specific
(Hamburg Quality of Life Questionnaire in Multiple
Sclerosis; HAQUAMS) and generic HRQOL (Profile of
Health-Related Quality of Life in Chronic Disorders;
PQOLC), with PQOLC being significantly improved at
study completion in the overall group and in subgroup
analyses for those with pre-intervention impairment, as
well as at six-month follow up in overall group and in
subgroup analyses. Similarly, HAQUAMS was signifi-
cantly improved at completion in the overall group and
in subgroup analyses in those with pre-intervention im-
pairment, as well as at six-month follow up in overall
group and subgroup analyses. Mills and Allen [41] re-
port an overall trend towards general symptom improve-
ment, but did not justify this statistically. Tavee et al.
[42] did not report population-specific results for the
Short Form-36 (SF-36). See Table 6.
Methodological quality of included papers
Quality was assessed using the Cochrane Collaboration
tool for Risk of Bias [39]. Of the 3 studies, only Grossman
et al. [40] adequately describe evidence of sequence ge-
neration at the randomisation stage. Allocation conceal-
ment was most convincingly implemented by Grossman
et al. [40], where the investigator was fully blinded to pa-
tient information, but this was not clearly described by
Mills and Allen [41]; Tavee et al. [42] appear to have
collected a control group independently of those ex-
pressing a desire to take part in the intervention group.
Only Grossman et al. [40] described blinding of outcome
assessors. All three authors described incomplete outcome
data, including attrition rates, but only Grossman et al.
[40] included this intention to treat and attrition data in
the statistical analysis. There was no substantive evidence
for selective outcome reporting in any of the studies,intervention effect size (p) Follow up effect size (p) and time point
0.39 (0.0006) 0.36 (0.02) at six months
1.00 (0.002) 0.64 (0.05) at six months
0.65 (0.00001) 0.36 (0.03) at six months
1.06 (0.0002) 0.66 (0.03) at six months
p > 0.05* p > 0.05*
p < 0.01* NR
es Depression Scale; 3. POMS - Profile of Mood States.
Table 5 Physical outcomes
Study Outcome (measure) Post intervention
effect size (p)
Follow up effect size (p)
and time point
Grossman et al. [40] Full intervention group Fatigue (MFIS) 0.41 (0.0001) 0.38 (0.001) at six months
Sub-group analysis 1.27 (0.0005) 1.09 (0.02) at six months
Mills and Allen [41] Fatigue (POMS) p > 0.05* NR
Single leg standing balance p < 0.05* p < 0.05* at three months
Tavee et al. [42] Fatigue (MFIS) p = 0.035* NR
Pain (VAS) p = 0.031* NR
PDDS p > 0.05* NR
1. MFIS - Modified Fatigue Index Scale; 2. POMS - Profile of Mood States; 3. VAS - Visual Analogue Scale for pain; 4. PDDS - Patient Determined Disease Steps;
5. NR - Not recorded; *Effect size not recorded.
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recording via Profile of Mood States (POMS), which
is described elsewhere [43]. Overall, only the study by
Grossman et al. [40] can be considered of high metho-
dological quality (see Table 7).
Discussion
This systematic review on the use of MBIs in people
with MS identified three studies eligible for inclusion,
which were varied in nature, with only one of the studies
being adequately powered to calculate meaningful effect
sizes (n = 150). Attrition rates across the studies were
variable, and the reasons for this are unclear. The MBIs
used in the studies were heterogenous. Two papers de-
scribed a protocol comparable to MBSR, but stemming
from Qi Gong practices; the other study closely resem-
bled a more standardised version of MBSR [34]. Two of
the interventions were applied in a hospital based group
setting; one was individualised and delivered one to one
in patients’ homes. There were a variety of measures of
interest recorded. However, none of the studies focussed
on our primary outcome of interest: perceived stress.
Results from the three studies are encouraging in the
domains of mental health and HRQOL. Improvements
in HRQOL, anxiety, depression, and fatigue remained
statistically significant at six-month follow up in the
Grossman et al. [40] study, albeit with diminished effect
sizes; standing balance remained significantly improved
at three-month follow up in the Mills and Allen [41]
study. There were no adverse events reported.Table 6 Quality of life outcomes
Study Measure Post int
Grossman et al. [40] Full intervention group HAQUAMS
PQOLC
Sub-group analysis HAQUAMS
PQOLC
1. HAQUAMS - Hamburg Quality of Life Questionnaire in Multiple Sclerosis (German
disorders (German).Strengths of this review
This review employed a rigorous methodological strat-
egy to search and appraise the research literature involv-
ing MBIs in people with MS. Three reviewers were
involved in the screening and appraisal of studies suit-
able for inclusion, with further discussion taking place,
as required. Quality was assessed in accordance with the
Cochrane Collaboration guidance.
Limitations of this review
The fact that MBIs originate from ancient oriental tradi-
tions may bias the results, in that, due to resource con-
straints, our review was limited to papers published in
English. The low methodological quality of two studies,
and the overall heterogenous nature of the studies, pre-
cluded quantitative meta-analysis.
Strengths and limitations of the included papers
Grossman et al. [40] produced a well designed RCT, with
adequate numbers being included to allow power calcula-
tions. Their strict inclusion/exclusion criteria, and widely
recognisable form of MBI, delivered by experienced, certi-
fied trainers, with pre-post and three-month follow up
measures being collected, allows a degree of confidence
when reviewing their findings. Mills and Allen [41] and
Tavee et al. [42] conducted studies that were of lower
methodological quality, with small sample sizes, and less
well-defined intervention standards. There was no random-
isation employed by Tavee et al. [42]. Comparing all three
studies, there is considerable heterogeneity with respect toervention effect size (p) Follow up effect size (p) and time point
0.43 (0.0002) 0.28 (0.04) at six months
0.86 (0.00000001) 0.51 (0.03) at six months
1.01 (0.0001) 0.58 (0.04) at six months
1.71 (0.00000001) 0.51 (0.003) at six months
); 2. PQOLC - Profile of Health-related Quality of Life in chronic
Table 7 Risk of bias summary
Grossman et al. [40] Mills and Allen [41] Tavee et al. [42]
Random sequence generation (selection bias) Low Unclear NA
Allocation concealment (selection bias) Low Unclear NA
Blinding of assessors (performance bias) Low Unclear High
Blinding of outcome assessment (detection bias) (patient reported outcomes) High High High
Incomplete outcome data addressed (attrition bias) Low Unclear High
Selective outcome reporting (reporting bias) Low High Unclear
Other sources of bias (ie baseline bias) Low Unclear Unclear
1. Low = Low risk of bias; 2. Unclear = Unclear risk of bias; 3. High = High risk of bias; 4. NA = Not available.
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most no meaningful information on the effects on different
socioeconomic groups. Limited information was provided
regarding different disease phenotypes and ‘stages’ of illness.
Furthermore, little evidence is available about economic
costs/benefits of the MBIs in this group, making drawing
conclusions about any individual MBI technique in this
population in general problematic. As such, these results
should be treated with caution.
Implications for research
Future studies of MBIs in people with MS should be of a
larger scale, employing robust methodological techniques.
They should examine physical and psychological measures;
different disease phenotypes, at various defined stages of
disease progression, of varied functional status; and should
address important questions around feasibility, acceptability
and appropriateness in diverse ethnic groups; as well as
economic concerns such as health care utilisation and cost
effectiveness. For specialist groups, such as people with MS,
it may be worth examining whether having classes run by
specialist trainers’ (i.e. health professionals) rather than
‘generic’ MBI trainers has any specific advantages/benefits.
Correlating findings with neuropsychological, bio-
marker and clinical imaging evidence would also be very
informative. Given the widely varying attrition rates re-
ported, qualitative research should also be employed to
gather information on the broad acceptability of MBIs
from the perspective of people with MS. Such research
could also explore perceived stress and self-efficacy, as
discussed previously.
Implications for practice
MBIs may have utility in the MS clinical population, par-
ticularly for mental health conditions, such as anxiety
and depression, as well as physical function. There is no
overt evidence of harm.
Conclusions
Although the evidence is limited, this review indicates
that MBIs can hold benefit for people with MS, specific-
ally in terms of quality of life, mental health, and somephysical aspects of the condition. It is unclear at this
time whether these results are generalisable to different
ethnic groups; both genders; all age groups; different dis-
ease phenotypes; and diverse socio-economic groups.
There is no evidence regarding health service utilisation
costs. It also remains unclear what benefit MBIs may
hold for people with more advanced MS. Further high
quality studies are needed to clarify the feasibility, practi-
cality, acceptability, health and psychosocial benefits of
MBIs for people with MS.
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